At the 2014 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 7-11 at the St. Louis Convention Center, Siemens Healthcare will debut syngo®.via for Molecular Imaging-a reading solution that transforms large amounts of data into comprehensive results, allowing for organ-based reading1, reference-based quantification2, and evidence-based reporting3 of disease. With syngo.via for Molecular Imaging, physicians are better able to focus on reading and can more easily produce high-quality diagnostic reports. Also at this year's SNMMI, Siemens will move from innovation to results, demonstrating the clinical adoption and efficacy of the two groundbreaking molecular imaging systems it introduced at last year's SNMMI annual meeting-the Biograph mCT Flow™4 positron emission tomography/computed tomography (PET/CT) system with continuous FlowMotion™ technology; and Symbia Intevo™4, the world's first xSPECT4 system, which completely integrates single-photon emission computed tomography (SPECT) and CT.

syngo.via for Molecular Imaging
Physicians expect clinical applications software to help better understand complex diseases at a functional level. The new syngo.via for Molecular Imaging provides unique and automated tools to visualize, measure, and report disease.


Now, physicians can immediately review all available information and perform organ-specific readings. For multiple time-point cases, prior studies are all registered with each other, even when acquired on multiple sources. The new Siemens-exclusive EQ PET algorithm harmonizes quantification of PET data based on National Electrical Manufacturers Association (NEMA) references. It allows standard uptake value (SUV) comparison in longitudinal patient exams for determination of cancer manifestation and change, independent of scanner make, model, or reconstruction algorithms. Neurology quantitative tools provide comparable results, which could potentially improve reader agreement for Alzheimer's disease evaluation. Cardiology quantitative tools improve therapy risk management of coronary artery disease with diagnostic blood flow quantification. Finally, with syngo.via structured reports, molecular imaging physicians will be key contributors to confident therapy decisions of the multi-disciplinary patient management team.

Biograph mCT Flow: One Year Later
At SNMMI 2013, Siemens first detailed how its revolutionary Biograph mCT Flow overcomes the limitations of conventional bed-based PET/CT with FlowMotion, a new technology that moves the patient smoothly through the system's gantry while continuously acquiring PET data. Biograph mCT Flow with FlowMotion advances routine image quality to a new level by enabling imaging protocols based on the organ's need. FlowMotion expands accurate and reproducible quantification in all dimensions for precise disease characterization in therapy monitoring, while enabling physicians to offer as low as reasonably achievable (ALARA) dose to every patient.

More HCB News